Naltrexone shown to help with Crohn's symptoms
Feb 2, 2007 - 11:49:11 AM
, Reviewed by: Dr. Sanjukta Acharya
|
|
|
"This is a novel approach to treating a common disease, and it's simple, it's safe, and it costs far less than current standards of treatment," Smith said. "We don't yet know the exact mechanisms involved in how it works, but we're working on that, as well."
|
|
Key Points of this article
|
|
Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
|
|
Naltrexone shown to improve symptoms of patients with Crohn's disease.
|
|
|
|
By Penn State College of Medicine,
[RxPG] A Penn State College of Medicine pilot study suggests a low dose of naltrexone, a drug used to ease symptoms of alcohol and drug addiction, may also bring relief to people with Crohn's disease, a chronic inflammatory disorder of the intestine that affects an estimated 500,000 Americans. The study results were released online this week in an early edition of the American Journal of Gastroenterology.
A team of researchers led by gastroenterologist Jill P. Smith, M.D., and Ian S. Zagon, Ph.D., Distinguished Professor of neural and behavioral sciences, at the College of Medicine and Penn State Milton S. Hershey Medical Center, received NIH funding last summer to initiate a phase 2 trial of low-dose naltrexone and Crohn's.
In the pilot study, patients with diagnosed Crohn's disease were treated with a low dose of naltrexone and monitored for improvement of symptoms for 12 weeks. Quality of life surveys were given every four weeks for 16 weeks. The results, published this week, show that 89 percent of participants showed an improvement with therapy, while 67 percent achieved remission of symptoms. The only side effect to treatment was sleep disturbance in some patients.
Typical treatment for Crohn's involves using steroids or corticosteroids, which suppress the immune system and can have other toxic side effects. Treatment is often time-intensive and expensive, as well.
"This is a novel approach to treating a common disease, and it's simple, it's safe, and it costs far less than current standards of treatment," Smith said. "We don't yet know the exact mechanisms involved in how it works, but we're working on that, as well."
| Funding information and declaration of competing interests:
The phase 2 study of naltrexone for Crohn's is also supported by funding by the Broad Medical Research Program.
|
|
Subscribe to Gastroenterology Newsletter
|
|
|
|
About Dr. Sanjukta Acharya
|
This news story has been reviewed by Dr. Sanjukta Acharya before its publication on RxPG News website. Dr. Sanjukta Acharya, MBBS is the chief editor for RxPG News website. She oversees all the medical news submissions and manages the medicine section of the website. She has a special interest in diabetes and endocrinology.
RxPG News is committed to promotion and implementation of Evidence Based Medical Journalism in all channels of mass media including internet.
|
|
Additional information about the news article
|
In a related study, Smith and other College of Medicine researchers are studying the chemical and molecular mechanisms involved in suppression of inflammatory responses in the intestine when animals are treated with naltrexone.
Team members on the first study include Heather Stock, M.S.I.V., Sandra Bingaman, R.N. and David Mauger, Ph.D., Department of Health Evaluation Sciences, Penn State College of Medicine.
Members of the second study team include Gail L. Matters, Ph.D., and John F. Harms, Ph.D., Department of Biochemistry and Molecular Biology; Leo Fitzpatrick, Ph.D., Department of Surgery; and Anuj Parikh, B.S., and Nicholas Nilo, Department of Medicine, Penn State College of Medicine.
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
